Effects of PPARγ and RBP4 Gene Variants on Metabolic Syndrome in HIV-Infected Patients with Anti-Retroviral Therapy

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Hung, Yuan Pin ^a,b   Lee, Nan Yao ^c   Lin, Sheng Hsiang ^a   Chang, Ho Ching ^d   Wu, Chi Jung ^a,e   Chang, Chia Ming ^c   Chen, Po Lin ^a,c   Lin, Hsiao Ju ^b,c   Wu, Yi Hui ^c,f   Tsai, Pei Jane ^a   Tsai, Yau Sheng ^a   Ko, Wen Chien ^a,c  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b Tainan Hospital   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^d CHI MEI MEDICAL CENTER   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^f PINGTUNG CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; HYPERGLYCEMIC AGENT; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOL BINDING PROTEIN 4; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ALLELE; ARTICLE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; TREATMENT DURATION;

ADULT; ALLELES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; RETINOL-BINDING PROTEINS, PLASMA; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84868673212     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049102     Document Type: Article

References (50)

1. Chen YM, Kuo SH, (2007) HIV-1 in Taiwan. Lancet 369: 623-625.
2. Michaels SH, Clark R, Kissinger P, (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 339: 405-406.
3. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860.
4. Behrens GM, Stoll M, Schmidt RE, (2000) Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf 23: 57-76.
5. Palacios R, Merchante N, Macias J, Gonzalez M, Castillo J, et al. (2006) Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy. Antivir Ther 11: 529-535.
6. Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, et al. (2007) Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 44: 726-734.
7. Jacobson DL, Tang AM, Spiegelman D, Thomas AM, Skinner S, et al. (2006) Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 43: 458-466.
8. Chang SY, Ko WS, Kao JT, Chang LY, Sun HY, et al. (2009) Association of single-nucleotide polymorphism 3 and c.553G>T of APOA5 with hypertriglyceridemia after treatment with highly active antiretroviral therapy containing protease inhibitors in hiv-infected individuals in Taiwan. Clin Infect Dis 48: 832-835.
9. Wu PY, Hung CC, Liu WC, Hsieh CY, Sun HY, et al. (2012) Metabolic syndrome among HIV-infected Taiwanese patients in the era of highly active antiretroviral therapy: prevalence and associated factors. J Antimicrob Chemother 67: 1001-1009.
10. Rosenkranz SL, Yarasheski KE, Para MF, Reichman RC, Morse GD, (2007) Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic Analysis. Metab Syndr Relat Disord 5: 163-173.
11. Tsai YS, Maeda N, (2005) PPARgamma: a critical determinant of body fat distribution in humans and mice. Trends Cardiovasc Med 15: 81-85.
12. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, et al. (1997) Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 241: 270-274.
13. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, et al. (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20: 284-287.
14. Tai ES, Corella D, Deurenberg-Yap M, Adiconis X, Chew SK, et al. (2004) Differential effects of the C1431T and Pro12Ala PPARgamma gene variants on plasma lipids and diabetes risk in an Asian population. J Lipid Res 45: 674-685.
15. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M, (2000) Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 268: 178-182.
16. Knouff C, Auwerx J, (2004) Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev 25: 899-918.
17. Kannisto K, Sutinen J, Korsheninnikova E, Fisher RM, Ehrenborg E, et al. (2003) Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS 17: 1753-1762.
18. Schindler K, Haider D, Wolzt M, Rieger A, Gmeinhart B, et al. (2006) Impact of antiretroviral therapy on visfatin and retinol-binding protein 4 in HIV-infected subjects. Eur J Clin Invest 36: 640-646.
19. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, et al. (2005) Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436: 356-362.
20. Yang B, Lin P, Carrick KM, McNulty JA, Clifton LG, et al. (2005) PPARgamma agonists diminish serum VEGF elevation in diet-induced insulin resistant SD rats and ZDF rats. Biochem Biophys Res Commun 334: 176-182.
21. van Hoek M, Dehghan A, Zillikens MC, Hofman A, Witteman JC, et al. (2008) An RBP4 promoter polymorphism increases risk of type 2 diabetes. Diabetologia 51: 1423-1428.
22. Munkhtulga L, Nakayama K, Utsumi N, Yanagisawa Y, Gotoh T, et al. (2007) Identification of a regulatory SNP in the retinol binding protein 4 gene associated with type 2 diabetes in Mongolia. Hum Genet 120: 879-888.
23. Kovacs P, Geyer M, Berndt J, Kloting N, Graham TE, et al. (2007) Effects of genetic variation in the human retinol binding protein-4 gene (RBP4) on insulin resistance and fat depot-specific mRNA expression. Diabetes 56: 3095-3100.
24. Han SH, Chin BS, Lee HS, Jeong SJ, Choi HK, et al. (2009) Serum retinol-binding protein 4 correlates with obesity, insulin resistance, and dyslipidemia in HIV-infected subjects receiving highly active antiretroviral therapy. Metabolism 58: 1523-1529.
25. Shah M, Tierney K, Adams-Huet B, Boonyavarakul A, Jacob K, et al. (2005) The role of diet, exercise and smoking in dyslipidaemia in HIV-infected patients with lipodystrophy. HIV Med 6: 291-298.
26. Mahan LK, Escott-Stump S (2000) Krause's food, nutrition, & diet therapy. Philadelphia: W.B. Saunders. xxxiv, 1194 p. p.
27. Gibson RS (2005) Principles of nutritional assessment. New York: Oxford University Press. xx, 908 p. p.
28. Miller M, Zhan M, Havas S, (2005) High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Intern Med 165: 2063-2068.
29. del Rincon Jarero JP, Aguilar-Salinas CA, Guillen-Pineda LE, Gomez-Perez FJ, Rull JA, (2002) Lack of agreement between the plasma lipid-based criteria and apoprotein B for the diagnosis of familial combined hyperlipidemia in members of familial combined hyperlipidemia kindreds. Metabolism 51: 218-224.
30. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
31. Cook RL, Zhu F, Belnap BH, Weber K, Cook JA, et al. (2009) Longitudinal trends in hazardous alcohol consumption among women with human immunodeficiency virus infection, 1995-2006. Am J Epidemiol 169: 1025-1032.
32. Miguez-Burbano MJ, Lewis JE, Malow R, (2009) Alcohol and race/ethnicity elicit different changes in lipid profiles in HIV-infected individuals receiving highly active antiretroviral therapy. J Assoc Nurses AIDS Care 20: 176-183.
33. Cheng DM, Libman H, Bridden C, Saitz R, Samet JH, (2009) Alcohol consumption and lipodystrophy in HIV-infected adults with alcohol problems. Alcohol 43: 65-71.
34. Petit JM, Carrat F, Duong M, Halfon P, Duvillard L, et al. (2010) Response to anti-HCV therapy in HIV-HCV-coinfected patients: does the lipid profile really have an effect? Antivir Ther 15: 797-800.
35. Yang LL, Hua Q, Liu RK, Yang Z, (2009) Association between two common polymorphisms of PPARgamma gene and metabolic syndrome families in a Chinese population. Arch Med Res 40: 89-96.
36. Joy T, Keogh HM, Hadigan C, Lee H, Dolan SE, et al. (2007) Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era. AIDS 21: 1591-1600.
37. Lagou V, Scott RA, Manios Y, Chen TL, Wang G, et al. (2008) Impact of peroxisome proliferator-activated receptors gamma and delta on adiposity in toddlers and preschoolers in the GENESIS Study. Obesity (Silver Spring) 16: 913-918.
38. Moffett SP, Feingold E, Barmada MM, Damcott CM, Marshall JA, et al. (2005) The C161->T polymorphism in peroxisome proliferator-activated receptor gamma, but not P12A, is associated with insulin resistance in Hispanic and non-Hispanic white women: evidence for another functional variant in peroxisome proliferator-activated receptor gamma. Metabolism 54: 1552-1556.
39. Valve R, Sivenius K, Miettinen R, Pihlajamaki J, Rissanen A, et al. (1999) Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 84: 3708-3712.
40. Nazih H, Raffi F, Taieb A, Reynes J, Choutet P, et al. (2011) Peroxisome Proliferator Activating Receptor (PPAR) Alpha and Gamma Polymorphisms and Metabolic Abnormalities in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy: The ANRS CO8 APROCO-COPILOTE Study. AIDS Res Hum Retroviruses.
41. Zanone Poma B, Riva A, Nasi M, Cicconi P, Broggini V, et al. (2008) Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS 22: 1769-1778.
42. Meirhaeghe A, Amouyel P, (2004) Impact of genetic variation of PPARgamma in humans. Mol Genet Metab 83: 93-102.
43. Mohamed MB, Mtiraoui N, Ezzidi I, Chaieb M, Mahjoub T, et al. (2007) Association of the peroxisome proliferator-activated receptor-gamma2 Pro12Ala but not the C1431T gene variants with lower body mass index in Type 2 diabetes. J Endocrinol Invest 30: 937-943.
44. Doney AS, Fischer B, Cecil JE, Boylan K, McGuigan FE, et al. (2004) Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes. Diabetologia 47: 555-558.
45. Saumoy M, Veloso S, Alonso-Villaverde C, Domingo P, Chacon MR, et al. (2009) PPARgamma Pro12Ala polymorphism in HIV-1-infected patients with HAART-related lipodystrophy. Curr HIV Res 7: 533-540.
46. Munkhtulga L, Nagashima S, Nakayama K, Utsumi N, Yanagisawa Y, et al. (2010) Regulatory SNP in the RBP4 gene modified the expression in adipocytes and associated with BMI. Obesity (Silver Spring) 18: 1006-1014.
47. Oh J, Hegele RA, (2007) HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis 7: 787-796.
48. van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, et al. (2004) Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 1: e19.
49. Parienti JJ, Massari V, Rey D, Poubeau P, Verdon R, (2007) Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study. Clin Infect Dis 45: 263-266.
50. Young J, Weber R, Rickenbach M, Furrer H, Bernasconi E, et al. (2005) Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther 10: 585-591.